299 related articles for article (PubMed ID: 34247896)
1. OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer.
Supiot S; Vaugier L; Pasquier D; Buthaud X; Magné N; Peiffert D; Sargos P; Crehange G; Pommier P; Loos G; Hasbini A; Latorzeff I; Silva M; Denis F; Lagrange JL; Morvan C; Campion L; Blanc-Lapierre A
Eur Urol; 2021 Oct; 80(4):405-414. PubMed ID: 34247896
[TBL] [Abstract][Full Text] [Related]
2. Long-term Outcomes and Patterns of Relapse Following High-dose Elective Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Nodes in Prostate Cancer: OLIGOPELVIS (GETUG-P07).
Vaugier L; Morvan C; Pasquier D; Buthaud X; Magné N; Beckendorf V; Sargos P; Crehange G; Pommier P; Loos G; Hasbini A; Latorzeff I; Silva M; Paul J; Blanc-Lapierre A; Supiot S
Eur Urol; 2024 Mar; ():. PubMed ID: 38490854
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.
Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Christiansen H; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M
Eur Urol Focus; 2021 Mar; 7(2):309-316. PubMed ID: 31495759
[TBL] [Abstract][Full Text] [Related]
4. OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer.
Supiot S; Rio E; Pacteau V; Mauboussin MH; Campion L; Pein F
BMC Cancer; 2015 Sep; 15():646. PubMed ID: 26408012
[TBL] [Abstract][Full Text] [Related]
5. PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.
De Bruycker A; Spiessens A; Dirix P; Koutsouvelis N; Semac I; Liefhooghe N; Gomez-Iturriaga A; Everaerts W; Otte F; Papachristofilou A; Scorsetti M; Shelan M; Siva S; Ameye F; Guckenberger M; Heikkilä R; Putora PM; Zapatero A; Conde-Moreno A; Couñago F; Vanhoutte F; Goetghebeur E; Reynders D; Zilli T; Ost P
BMC Cancer; 2020 May; 20(1):406. PubMed ID: 32398040
[TBL] [Abstract][Full Text] [Related]
6. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial.
Ost P; Siva S; Brabrand S; Dirix P; Liefhooghe N; Otte FX; Gomez-Iturriaga A; Everaerts W; Shelan M; Conde-Moreno A; López Campos F; Papachristofilou A; Guckenberger M; Scorsetti M; Zapatero A; Villafranca Iturre AE; Eito C; Couñago F; Muto P; Van De Voorde L; Mach N; Bultijnck R; Fonteyne V; Moon D; Thon K; Mercier C; Achard V; Stellamans K; Goetghebeur E; Reynders D; Zilli T
Eur Urol Oncol; 2024 Jun; 7(3):462-468. PubMed ID: 37821242
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer : An investigation of 117 pelvic lymph nodes.
Cozzi S; Botti A; Timon G; Blandino G; Najafi M; Manicone M; Bardoscia L; Ruggieri MP; Ciammella P; Iotti C
Strahlenther Onkol; 2022 Aug; 198(8):700-709. PubMed ID: 34757443
[TBL] [Abstract][Full Text] [Related]
8. Salvage radiotherapy in patients affected by oligorecurrent pelvic nodal prostate cancer.
Ingrosso G; Mariucci C; Tenti MV; Bini V; Alì E; Saldi S; Palumbo I; Bellavita R; Aristei C
Clin Transl Oncol; 2020 Dec; 22(12):2236-2243. PubMed ID: 32418156
[TBL] [Abstract][Full Text] [Related]
9. Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07).
Vaugier L; Palpacuer C; Rio E; Goineau A; Pasquier D; Buthaud X; De Laroche G; Beckendorf V; Sargos P; Créhange G; Pommier P; Loos G; Hasbini A; Latorzeff I; Silva M; Denis F; Lagrange JL; Campion L; Supiot S
Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1061-1067. PubMed ID: 30557672
[TBL] [Abstract][Full Text] [Related]
10. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.
Steuber T; Jilg C; Tennstedt P; De Bruycker A; Tilki D; Decaestecker K; Zilli T; Jereczek-Fossa BA; Wetterauer U; Grosu AL; Schultze-Seemann W; Heinzer H; Graefen M; Morlacco A; Karnes RJ; Ost P
Eur Urol Focus; 2019 Nov; 5(6):1007-1013. PubMed ID: 29530632
[TBL] [Abstract][Full Text] [Related]
11. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
[TBL] [Abstract][Full Text] [Related]
12. Prostatectomy Bed Image-guided Dose-escalated Salvage Radiotherapy (SPIDER): An International Multicenter Retrospective Study.
Benziane-Ouaritini N; Zilli T; Giraud A; Ingrosso G; Di Staso M; Trippa F; Pommier P; Meyer E; Francolini G; Schick U; Pasquier D; Marc Cosset J; Magne N; Martin E; Gnep K; Renard-Penna R; Anger E; Achard V; Giraud N; Aristei C; Ferrari V; Pasquier C; Zaine H; Osman O; Detti B; Perennec T; Mihoci I; Supiot S; Latorzeff I; Sargos P
Eur Urol Oncol; 2023 Aug; 6(4):390-398. PubMed ID: 37059627
[TBL] [Abstract][Full Text] [Related]
13. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
De Bleser E; Jereczek-Fossa BA; Pasquier D; Zilli T; Van As N; Siva S; Fodor A; Dirix P; Gomez-Iturriaga A; Trippa F; Detti B; Ingrosso G; Triggiani L; Bruni A; Alongi F; Reynders D; De Meerleer G; Surgo A; Loukili K; Miralbell R; Silva P; Chander S; Di Muzio NG; Maranzano E; Francolini G; Lancia A; Tree A; Deantoni CL; Ponti E; Marvaso G; Goetghebeur E; Ost P
Eur Urol; 2019 Dec; 76(6):732-739. PubMed ID: 31331782
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy.
Milenkovic U; Kuijk J; Roussel E; Devos G; Van den Broeck T; Van Eecke H; Vanderstichele A; Duvillier T; Verhamme L; Van Haute W; Goeman L; Berghen C; Joniau S; De Meerleer G
Eur Urol Oncol; 2023 Dec; 6(6):582-589. PubMed ID: 36878753
[TBL] [Abstract][Full Text] [Related]
15. LUNAR: a randomized Phase 2 study of
Ma TM; Czernin J; Felix C; Alano R; Wilhalme H; Valle L; Steinberg ML; Dahlbom M; Reiter RE; Rettig MB; Cao M; Calais J; Kishan AU
BJU Int; 2023 Jul; 132(1):65-74. PubMed ID: 36797449
[TBL] [Abstract][Full Text] [Related]
16. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought.
Bravi CA; Fossati N; Gandaglia G; Suardi N; Mazzone E; Robesti D; Osmonov D; Juenemann KP; Boeri L; Jeffrey Karnes R; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
Eur Urol; 2020 Nov; 78(5):661-669. PubMed ID: 32624288
[TBL] [Abstract][Full Text] [Related]
17. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
Pollack A; Karrison TG; Balogh AG; Gomella LG; Low DA; Bruner DW; Wefel JS; Martin AG; Michalski JM; Angyalfi SJ; Lukka H; Faria SL; Rodrigues GB; Beauchemin MC; Lee RJ; Seaward SA; Allen AM; Monitto DC; Seiferheld W; Sartor O; Feng F; Sandler HM
Lancet; 2022 May; 399(10338):1886-1901. PubMed ID: 35569466
[TBL] [Abstract][Full Text] [Related]
18. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
Ost P; Reynders D; Decaestecker K; Fonteyne V; Lumen N; De Bruycker A; Lambert B; Delrue L; Bultijnck R; Claeys T; Goetghebeur E; Villeirs G; De Man K; Ameye F; Billiet I; Joniau S; Vanhaverbeke F; De Meerleer G
J Clin Oncol; 2018 Feb; 36(5):446-453. PubMed ID: 29240541
[TBL] [Abstract][Full Text] [Related]
19. Pattern of Recurrence After Stereotactic Radiotherapy in Prostate Cancer Patients With Nodal Pelvic Relapse. A Multi-Institutional Retrospective Analysis.
Francolini G; Bellini C; Di Cataldo V; Detti B; Bruni A; Alicino G; Triggiani L; La Mattina S; D'Angelillo RM; Demofonti C; Mazzola R; Cuccia F; Alongi F; Aquilano M; Allegra AG; Ciccone LP; Burchini L; Salvestrini V; Morelli I; Frosini G; Desideri I; Livi L
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):57-62. PubMed ID: 34598843
[TBL] [Abstract][Full Text] [Related]
20. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
